1. Medtech Insight
  2. >>Policy & Regulation

CMS Clarifies Criterion To Evaluate New Tech Add-On Payments In Inpatient Rule

 
• By Sue Darcey

The US Medicare agency revised and clarified its policies on how it evaluates new technology add-on payments and highlighted its new policy on payments for FDA-approved breakthrough devices, in a final 2020 Inpatient Prospective Payment System (IPPS) rule released on 5 August.

An image of a nice clock with time for new technology - Illustration
CMS made some important revisions to the way it evaluats new technology add-on payments in a new IPPS rule

The US Centers for Medicare and Medicaid Services (CMS) codified an alternative new technology add-on payment (NTAP) pathway for Food and Drug Administration-approved breakthrough devices, while updating “substantial clinical improvement” NTAP review policies, in a new Inpatient Prospective Payment System (IPPS) rule.

The changes were made to incentivize creation of new technologies to treat Medicare beneficiaries, and better help device and diagnostic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

Oura Gets Competitors Banned From US Market, But Faces Ultrahuman Countersuit

 
• By Elizabeth Orr

The US International Trade Commission has banned smart rings from Ultrahuman and RingConn after Oura Health's patent infringement case. Ultrahuman countersued, claiming Oura infringes its intellectual property. Sales and marketing of the affected rings will cease on October 22.

A Decade Of Breakthrough Devices: Cardiac And Orthopedic Products Dominate FDA Designations

 
• By Brian Bossetta and Elizabeth Orr

The US FDA has provided an update on its breakthrough devices program, now 10 years running. Cardiac, orthopedic, and neurological devices have received the most designations, while only one has been awarded to an obstetrics/gynecology product.

Study Finds Public Companies Behind Most Recalled AI Devices

 
• By Elizabeth Orr

A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.

Four-Year Waits, 60-Page NCDs: Consultant Urges Medicare Overhaul

 
• By Elizabeth Orr

Medicare’s device coverage process is “a system in crisis,” consultant Bruce Quinn warned at the NextGen Dx Summit. He criticized bloated NCDs, stalled advisory committees, and years-long delays, urging CMS to streamline LCDs and adopt a six-month “fast-track” model to speed innovation access.

More from Medtech Insight

Study Finds Public Companies Behind Most Recalled AI Devices

 
• By Elizabeth Orr

A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.

Reports Put $4B Price Tag On Versius Maker CMR. Will This Change Surgical Robot Valuation?

 
• By Barnaby Pickering

The value proposition of surgical robots is quickly changing. Gone is the focus on benefit to patients; instead cost, operative efficiency and surgeon longevity are the new focal points, making deciphering M&A value much more difficult.

Four-Year Waits, 60-Page NCDs: Consultant Urges Medicare Overhaul

 
• By Elizabeth Orr

Medicare’s device coverage process is “a system in crisis,” consultant Bruce Quinn warned at the NextGen Dx Summit. He criticized bloated NCDs, stalled advisory committees, and years-long delays, urging CMS to streamline LCDs and adopt a six-month “fast-track” model to speed innovation access.